Description

Opdivo Injection (Nivolumab) 240mg/24ml – Uses, Side Effects, Dosage & Price in Pakistan

Opdivo Injection (Nivolumab) 240mg/24ml is a prescription immunotherapy medicine used to treat several types of cancer. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody. Unlike traditional chemotherapy, nivolumab works by helping the body’s immune system recognize and attack cancer cells.

Opdivo 240mg/24ml is supplied as a single-dose vial containing nivolumab at a concentration of 10mg/mL. It is administered through an intravenous (IV) infusion by a qualified healthcare professional. The appropriate use, dosage, and treatment duration depend on the type and stage of cancer and whether Opdivo is being used alone or with other anticancer medicines.

Because Opdivo is a prescription oncology medicine, it should only be administered under the supervision of an oncologist or appropriately trained healthcare professional.

Opdivo Injection (Nivolumab) Used For

Opdivo 240mg/24ml is used in different cancer treatment settings. Depending on the patient’s diagnosis, it may be given alone or in combination with medicines such as ipilimumab, chemotherapy, or other targeted treatments.

Current prescribing information includes uses for several cancers, including:

• Certain types of unresectable or metastatic melanoma.
• Certain patients with non-small cell lung cancer (NSCLC).
• Certain patients with renal cell carcinoma.
• Classical Hodgkin lymphoma.
• Certain cancers of the head and neck.
• Certain types of urothelial carcinoma.
• Esophageal squamous cell carcinoma.
• Certain gastric, gastroesophageal junction, and esophageal adenocarcinomas.
• Certain patients with hepatocellular carcinoma.
• MSI-H or dMMR metastatic colorectal cancer in appropriate treatment settings.
• Certain resected esophageal or gastroesophageal junction cancers as adjuvant treatment.

The exact indication depends on the cancer type, stage, previous treatment, biomarker results when applicable, and the patient’s overall treatment plan.

How Opdivo Injection (Nivolumab) Works

Nivolumab is a PD-1 immune checkpoint inhibitor. PD-1 is a receptor found on immune cells called T cells. Some cancer cells can use the PD-1 pathway to reduce the immune system’s ability to recognize and attack them.

Opdivo binds to PD-1 and blocks its interaction with certain ligands, including PD-L1 and PD-L2. This can help restore T-cell activity against cancer cells.

Because Opdivo changes immune-system activity, its effects can extend beyond cancer cells and may sometimes cause the immune system to attack healthy organs. This is why patients receiving nivolumab require appropriate monitoring during treatment.

Opdivo 240mg/24ml Dosage

The appropriate Opdivo dosage depends on the type of cancer and whether it is being used alone or with other medicines.

For several approved adult indications, a commonly used single-agent regimen is 240mg every 2 weeks or 480mg every 4 weeks. Opdivo is administered as an intravenous infusion, generally over approximately 30 minutes. Some combination treatment regimens use weight-based doses or different schedules.

Treatment may continue until disease progression, unacceptable toxicity, or for a specified duration depending on the indication.

The 240mg/24ml vial should not be self-administered. A healthcare professional prepares and administers the infusion according to the prescribing information and the patient’s treatment plan.

How to Take Opdivo Injection

Opdivo is not a medicine that patients take by mouth. It is administered through an intravenous infusion.

The healthcare professional prepares the required dose and dilutes it according to the approved instructions before administration. Opdivo may be diluted with 0.9% sodium chloride injection or 5% dextrose injection to an appropriate final concentration.

The infusion is given through an IV line using appropriate equipment. Opdivo should not be shaken, and the vial is intended for single use.

Patients should attend every scheduled infusion appointment and inform their oncology team if they experience new symptoms between treatments.

Opdivo Injection Side Effects

Opdivo can cause side effects, although not every patient experiences them. Some commonly reported adverse reactions can include:

• Fatigue
• Rash
• Diarrhea
• Nausea
• Decreased appetite
• Cough
• Muscle or joint pain
• Constipation
• Abdominal pain
• Shortness of breath
• Infusion-related reactions
• Changes in thyroid function or other laboratory results

Side effects can vary depending on whether nivolumab is used alone or together with other anticancer medicines.

Patients should tell their healthcare professional about persistent or troublesome symptoms rather than stopping treatment themselves.

Serious Side Effects and Warnings

Because nivolumab activates immune responses, it can cause immune-mediated adverse reactions that may affect different organs. These reactions can sometimes become serious or life-threatening.

Important warning signs include:

• Pneumonitis: New or worsening cough, chest pain, or shortness of breath.
• Colitis: Persistent diarrhea, abdominal pain, or blood or mucus in the stool.
• Hepatitis: Yellowing of the skin or eyes, dark urine, unusual tiredness, or abnormal liver tests.
• Endocrine disorders: Unusual fatigue, headache, weight changes, dizziness, or changes in thyroid or adrenal function.
• Nephritis: Reduced urine output or other signs of kidney problems.
• Skin reactions: Severe rash, blistering, peeling, or painful skin changes.
• Encephalitis or other neurological reactions: Confusion, weakness, seizures, or other unusual neurological symptoms.
• Myocarditis: Chest pain, shortness of breath, palpitations, or unusual fatigue.
• Infusion reactions: Chills, fever, flushing, dizziness, breathing difficulty, or other symptoms occurring during or shortly after infusion.

Immune-mediated reactions may require treatment interruption, corticosteroids, or other medical management depending on severity.

Seek urgent medical attention if severe breathing difficulty, chest pain, severe abdominal symptoms, confusion, significant weakness, or serious allergic or infusion-related symptoms occur.

Precautions Before Using Opdivo 240mg/24ml

Before receiving Opdivo, tell your oncologist about your medical history and all medicines you use.

Your doctor should know if you have:

• Previous immune-related complications from cancer treatment
• Lung disease
• Liver problems
• Kidney disease
• Thyroid or other endocrine disorders
• Autoimmune conditions
• A history of organ transplantation
• Previous severe reactions to immunotherapy

Tell your healthcare team about prescription medicines, over-the-counter medicines, vitamins, and supplements.

Regular laboratory tests and clinical monitoring may be required throughout treatment.

Opdivo Drug Interactions

Nivolumab does not have the same conventional drug-interaction profile as many small-molecule medicines because it is a monoclonal antibody. However, medicines that affect the immune system may be clinically important during treatment.

Patients should tell their doctor about corticosteroids, immunosuppressive medicines, cancer treatments, and all other medicines or supplements they are taking.

Do not start or stop an important medicine without discussing it with your treating healthcare professional.

Opdivo During Pregnancy

Opdivo may cause fetal harm because it affects immune-system activity. Women who can become pregnant should discuss appropriate contraception with their healthcare professional before starting treatment.

If pregnancy occurs during treatment with nivolumab, the patient should contact the treating oncologist promptly.

Breastfeeding should also be discussed with a healthcare professional. The potential risks to a nursing infant need to be considered before breastfeeding during treatment.

Opdivo Monitoring

Regular monitoring is an important part of treatment with Opdivo 240mg/24ml. Depending on the cancer and treatment combination, the healthcare team may monitor:

• Liver function
• Kidney function
• Thyroid function
• Blood counts
• Blood glucose
• Lung symptoms
• Skin changes
• Gastrointestinal symptoms
• Neurological symptoms
• Cardiac symptoms
• Treatment response through appropriate imaging and clinical assessment

Monitoring helps doctors identify immune-mediated adverse reactions early and determine whether treatment should continue, be temporarily withheld, or be discontinued.

Opdivo Injection Storage

Opdivo 240mg/24ml should be stored according to the official product requirements. The unopened vial should generally be refrigerated at 2°C to 8°C and protected from light in its original packaging.

The product should not be frozen or shaken. Opdivo is supplied as a single-dose vial, and unused medicine should be discarded according to applicable handling requirements.

Because this is an injectable oncology medicine, preparation, storage, dilution, and administration should be handled by trained healthcare professionals.

Opdivo 240mg/24ml Price in Pakistan

The Opdivo Injection 240mg/24ml price in Pakistan can vary depending on imported stock, supplier, availability, exchange rates, and market conditions. Oncology medicines may have changing prices because of import and supply factors.

For the latest Opdivo 240mg/24ml price in Pakistan, customers can contact Impo Medic to confirm current availability, product details, and price before ordering.

How to Buy Opdivo Injection 240mg/24ml in Pakistan

Patients looking for Opdivo Injection (Nivolumab) 240mg/24ml in Pakistan should obtain this prescription oncology medicine through a reliable pharmaceutical supplier.

Before purchasing, verify the medicine name, strength, vial size, batch information, expiry date, packaging condition, and storage requirements. Opdivo should only be used according to an oncologist’s treatment plan.

Impo Medic can be contacted to check the current availability and price of Opdivo Injection 240mg/24ml in Pakistan.

Frequently Asked Questions About Opdivo Injection (Nivolumab) 240mg/24ml

What is Opdivo Injection (Nivolumab) 240mg/24ml used for?

Opdivo contains nivolumab, an immune checkpoint inhibitor used for several types of cancer, including certain cases of melanoma, lung cancer, kidney cancer, head and neck cancer, urothelial cancer, esophageal cancer, and other approved indications. The exact use depends on the patient’s diagnosis and treatment plan.

How is Opdivo 240mg/24ml administered?

Opdivo 240mg/24ml is administered through an intravenous infusion by a qualified healthcare professional. For many single-agent indications, 240mg is given every 2 weeks, although some patients may receive 480mg every 4 weeks or another regimen depending on the indication.

Is Opdivo a chemotherapy medicine?

Opdivo is not traditional cytotoxic chemotherapy. It is an immunotherapy medicine that blocks the PD-1 immune checkpoint and helps restore immune activity against cancer cells.

What are the common Opdivo side effects?

Common side effects may include fatigue, rash, diarrhea, nausea, decreased appetite, cough, muscle or joint pain, and other treatment-related effects. Side effects can differ when Opdivo is combined with other cancer medicines.

Can Opdivo cause serious side effects?

Yes. Opdivo can cause immune-mediated reactions affecting the lungs, liver, intestines, kidneys, endocrine organs, skin, heart, nervous system, and other organs. New or worsening symptoms should be reported to the healthcare team promptly.

How should Opdivo 240mg/24ml be stored?

The unopened vial should generally be refrigerated at 2°C to 8°C, protected from light, and should not be frozen or shaken.

Can I buy Opdivo 240mg/24ml in Pakistan?

Availability and price may vary for imported oncology medicines. You can contact Impo Medic to check the current availability and price of Opdivo Injection 240mg/24ml in Pakistan.

How long does Opdivo treatment continue?

Treatment duration depends on the cancer type, treatment regimen, response to therapy, and side effects. Depending on the indication, treatment may continue until disease progression, unacceptable toxicity, or a specified maximum treatment duration.